JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Nanotheranostic Structures for Diagnostics and Therapeutics in Personalized Medicine

Esther P*[1], Jahnavi Bhavani K[2], Navya Kalisetti[2], R. N. J. H. Keerthi N[2], Sri Lakshmi Durga Sravanthi G[2], Devika K[2], Narayana Raju P[3], Bhaskara Raju V[4], Ajay Ratnam M[1]

[1] *Assistant Professor, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*
[2] *UG Scholar, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*
[3] *Professor, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*
[4] *Principal and Professor, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*

Publication history: Received on 17th October 2025; Revised on 1st November 2025; Accepted on 6th November 2025

Article DOI: 10.69613/jh2dqe17

Abstract: Nanotheranostics play a transformative role in biomedical engineering, merging diagnostic and therapeutic functionalities into singular nanoscale platforms to facilitate precision medicine. This convergent technique combats the limitations of conventional medical interventions by enabling simultaneous disease detection, targeted drug delivery, and real-time monitoring of therapeutic efficacy. Theranostic systems offer enhanced biodistribution and reduced systemic toxicity by leveraging the unique physicochemical properties of materials such as lipids, polymers, inorganic metals, and carbon nanostructures. The integration of imaging modalities including magnetic resonance imaging, computed tomography, and fluorescence with controlled release mechanisms allows for a "see and treat" strategy, particularly vital in oncology, neurology, and infectious disease management. Recent advancements in surface functionalization and biomarker targeting have optimized the accumulation of these agents at pathological sites, overcoming biological barriers such as the blood-brain barrier. However, the translation of these technologies from bench to bedside remains hindered by challenges related to large-scale manufacturing, long-term biocompatibility, and regulatory complexities. Research must focus on the elucidation of catalytic mechanisms, such as those found in nanozymes, and the development of sustainable synthesis methods to ensure clinical viability. This review discusses about the classification, fabrication, mechanistic principles, and clinical applications of nanotheranostic agents, highlighting their potential to redefine healthcare paradigms through adaptive and individualized treatment regimens.

Keywords: Nanomedicine; Theranostics; Targeted Delivery; Bioimaging; Personalized Healthcare

1. Introduction

The paradigm of modern medicine is undergoing a fundamental shift from a "one-size-fits-all" model to personalized or precision medicine, a transition significantly accelerated by the advent of nanotheranostics. This emerging field represents the convergence of nanotechnology with pharmaceutical science and diagnostic imaging, utilizing customized nanoscale materials to integrate therapeutic and diagnostic capabilities within a single platform. The portmanteau "theranostics" was first introduced by John Funkhouser in 1998, conceptualized to describe the development of disparate tools for identifying and treating pathologies into a cohesive, integrated system [1]. This integration addresses one of the most critical gaps in contemporary healthcare: the ability to receive precise, real-time feedback on the biodistribution and efficacy of a therapeutic agent during the course of treatment.

In the early 21st century, the stagnation in the development of novel medical instrumentation prompted regulatory bodies, including the United States Food and Drug Administration (FDA), to call for a concerted modernization of scientific tools. In 2004, the FDA's Critical Path Initiative emphasized that the decline in innovative medical products was partly due to the inability of traditional tools to evaluate the safety and efficacy of new candidates efficiently [2]. Nanotechnology emerged as a potent solution to these challenges, offering materials with unique physicochemical properties such as ultra-small size, high surface-area-to-volume ratio, and tunable surface chemistry that are distinct from their bulk counterparts. These properties enable nanotheranostic agents to navigate the complex biological milieu, crossing physiological barriers that typically impede conventional drugs.

The core philosophy of nanotheranostics is the "see and treat" strategy. Conventional therapeutic regimens often involve a "trial and error" approach, where a diagnosis is made, a standard therapy is administered, and the patient is monitored over weeks or

* Corresponding author: Esther P

Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

months to determine efficacy. In contrast, a nanotheranostic system allows clinicians to detect a specific molecular signature of a disease, deliver a targeted therapeutic payload to that site, and simultaneously monitor the drug's accumulation and the biological response [3]. This capability is particularly vital for diseases like cancer, where tumor heterogeneity can lead to variable drug responses among patients, or even within different tumors in the same patient. By combining imaging agents (such as iron oxide for MRI or gold nanoparticles for CT) with therapeutic agents (chemotherapeutics, nucleic acids, or thermal absorbers), nanotheranostics provides a visual confirmation of drug delivery and immediate data on treatment success.

Moreover, the clinical imperative for such technologies extends beyond efficacy to safety and accessibility. Traditional systemic chemotherapy is notorious for its dose-limiting toxicities, caused by the non-specific distribution of cytotoxic drugs to healthy tissues. Nanotheranostics ameliorates this by exploiting the enhanced permeability and retention (EPR) effect in solid tumors and utilizing specific ligand-receptor interactions to localize treatment, thereby maximizing the therapeutic index [4]. Additionally, as highlighted in global health discussions, the integration of diagnosis and therapy into a single intervention has the potential to streamline healthcare delivery. In resource-limited settings where access to separate high-end diagnostic and therapeutic facilities may be fragmented, a unified nanotherapeutic modality could theoretically reduce the logistical burden and cost of patient management, provided that manufacturing scales can be economically optimized. Thus, nanotheranostics stands not merely as a technological novelty, but as a necessary evolution in the quest for highly specific, patient-centric, and adaptive healthcare interventions.

2. Advantages and Limitations of Theranostic Systems

2.1. Therapeutic and Diagnostic Efficacy

The primary advantage of nanotheranostic systems lies in their ability to streamline patient care and enhance clinical outcomes. By combining diagnosis and therapy, these systems reduce the complexity of treatment protocols and potentially lower healthcare costs through simplified fabrication and administration processes. Theranostic formulations exhibit enhanced chemical and thermal stability, ensuring prolonged shelf life and consistent performance under physiological conditions [5]. Furthermore, the ability to surface-functionalize these particles with ligands, antibodies, or aptamers enables active targeting of diseased tissues, such as tumors, thereby significantly reducing cytotoxicity to healthy cells. This targeted approach aligns with the objectives of precision medicine, allowing for the customization of dosage and treatment duration based on real-time imaging feedback [6].

2.2. Biocompatibility and Catalytic Challenges

Despite these advantages, the clinical translation of nanotheranostics faces substantial hurdles regarding safety and material interaction. A significant concern is the long-term biosafety and potential toxicity of nanomaterials, particularly those composed of inorganic elements that may persist in the liver or kidneys, leading to oxidative stress or inflammation. While materials like nanozymes nanomaterials with intrinsic enzyme-like characteristics offer robust catalytic activity and stability compared to natural enzymes, their interactions with biological substrates must be carefully controlled to prevent adverse immunological reactions [7]. Current research is heavily focused on understanding the structure-activity relationships of these materials, specifically expanding beyond simple oxidoreductase activities to include transferases, isomerases, and lyases, to enhance their therapeutic utility while ensuring patient safety [8].

3. Classification of Nanotheranostic Agents

Theranostic nanoparticles are categorized based on their material composition, each offering distinct advantages for imaging and drug delivery.

3.1. Lipid-Based Nanocarriers

Lipid-based nanoparticles (LNPs) and liposomes represent the most clinically established class of nanocarriers due to their structural similarity to biological membranes. Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate hydrophilic drugs within their aqueous core and hydrophobic agents within the lipid membrane [9]. This dual-loading capability makes them highly versatile. Recent developments have expanded their utility beyond traditional chemotherapy delivery (e.g., liposomal doxorubicin) to include labile genetic materials such as mRNA and siRNA. As demonstrated by their pivotal role in COVID-19 vaccines and treatments for amyloidosis, these systems effectively protect therapeutic payloads from enzymatic degradation and improve cellular uptake [10].

3.2. Polymeric Nanostructures

Polymeric nanoparticles utilize biodegradable polymers like polylactic-co-glycolic acid (PLGA) or chitosan to create robust delivery vehicles. These particles can be engineered to release their cargo in response to specific physiological triggers, such as pH changes or enzymatic activity found within tumor microenvironments [11]. The polymer matrix protects the drug from premature release and degradation. Moreover, the surface of polymeric nanoparticles is frequently modified with polyethylene glycol (PEG) in a process known as PEGylation. This modification creates a hydration layer that prevents protein adsorption (opsonization), thereby prolonging circulation time and allowing the particles to evade immune sequestration by the reticuloendothelial system.

Table 1. Classification and Characteristics of Major Nanotheranostic Platforms

Class	Examples	Advantages	Diagnostic Use	Therapeutic Use
Lipid-Based	Liposomes, Solid Lipid Nanoparticles (SLNs)	High biocompatibility, dual drug loading (hydrophilic/phobic), established clinical track record.	MRI (when loaded with Gd/Fe), Fluorescence imaging.	Delivery of chemotherapy, mRNA/siRNA, and proteins.
Polymeric	PLGA, Chitosan, Dendrimers	Biodegradable, highly tunable surface chemistry, controlled release profiles.	Optical imaging, CT contrast (when iodinated).	Sustained drug release, gene delivery.
Inorganic	Gold (AuNPs), Silver (AgNPs), Silica (MSNs)	Unique optical/electronic properties, tunable size/shape, high stability.	CT contrast, SERS detection, Photoacoustic imaging.	Photothermal therapy (PTT), antimicrobial action.
Magnetic	Iron Oxide (SPIONs), Manganese Oxide	Superparamagnetism, non-invasive manipulation by external fields.	T2-weighted MRI contrast.	Magnetic hyperthermia, magnetic drug targeting.
Carbon-Based	Carbon Nanotubes (CNTs), Graphene Oxide	High surface area for loading, high mechanical strength, near-infrared absorption.	Photoacoustic imaging, Raman mapping.	Photothermal ablation, high-capacity drug delivery.

3.3. Inorganic Nanoparticles

Inorganic materials provide intrinsic physical properties suitable for imaging and external stimuli-responsive therapy.

3.3.1. Gold Nanoparticles (AuNPs)

Gold nanoparticles are distinguished by their surface plasmon resonance (SPR) properties, which can be tuned by altering the particle's size and shape (e.g., nanoshells, nanostars). This property makes them excellent candidates for computed tomography (CT) contrast agents due to their high X-ray attenuation coefficient. Therapeutically, they are utilized in photothermal therapy (PTT), where they convert absorbed near-infrared light into localized heat to ablate cancer cells without damaging surrounding tissue [12].

3.3.2. Silica Nanoparticles

Mesoporous silica nanoparticles (MSNs) are characterized by their rigid framework, large internal surface area, and tunable pore sizes. These features allow for exceptionally high drug loading capacities. MSNs are often engineered with "gatekeeper" molecules functional groups or caps covering the pores that release the entrapped drug only upon reaching the target tissue or in response to specific stimuli, offering precise spatiotemporal control over drug delivery [13].

3.3.3. Silver Nanoparticles (AgNPs)

Known historically for their potent antimicrobial properties, silver nanoparticles are being repurposed for infectious disease theranostics. They disrupt bacterial cell walls and metabolic pathways through the release of silver ions and generation of reactive oxygen species. Additionally, their unique optical properties allow for detection via surface-enhanced Raman scattering (SERS), enabling the sensitive identification of pathogens [14].

3.4. Magnetic and Carbon-Based Systems

3.4.1. Iron Oxide Nanoparticles (IONPs)

Superparamagnetic iron oxide nanoparticles (SPIONs) are premier contrast agents for magnetic resonance imaging (MRI), providing negative (T2) contrast enhancement. Their superparamagnetic nature means they exhibit magnetic properties only in the presence of an external magnetic field, preventing aggregation in the bloodstream. Therapeutically, they are used in magnetic hyperthermia, where an alternating magnetic field causes the particles to oscillate and generate heat, destroying malignant tissue [15].



Figure 1. Classification of Nanotheranostics

3.4.2. Carbon Nanotubes and Graphene

Carbon-based nanomaterials, including carbon nanotubes (CNTs) and graphene oxide, exhibit exceptional electrical, thermal, and mechanical properties. Their large surface area permits high-density drug loading via pi-pi stacking interactions. Their intrinsic optical absorption in the near-infrared region is utilized for photothermal ablation. However, concerns regarding their non-biodegradability, potential for causing pulmonary inflammation, and cytotoxicity require rigorous toxicity profiling before widespread clinical adoption [16].

3.5. Hybrid and Composite Systems

To maximize efficacy, hybrid systems combine organic and inorganic materials, often in a core-shell architecture. For instance, a magnetic iron oxide core may be coated with a biocompatible silica or polymer shell. This architecture preserves the magnetic properties for MRI while the shell facilitates drug encapsulation and surface bioconjugation, creating a multifunctional platform that exerts synergistic therapeutic effects [17].

4. Mechanism of Action

4.1. Targeting Mechanisms

The efficacy of nanotheranostics relies on rational design parameters such as size, charge, and surface chemistry to navigate the body. Passive targeting utilizes the enhanced permeability and retention (EPR) effect, where the leaky vasculature and poor lymphatic drainage characteristic of solid tumors allow nanoparticles to accumulate preferentially in tumor tissue. Active targeting enhances this specificity by conjugating ligands such as antibodies, aptamers, or peptides to the nanoparticle surface. These ligands facilitate binding to overexpressed receptors on diseased cells, such as folate receptors on various carcinomas, thereby increasing intracellular accumulation [18].



Figure 2. Mechanism of Nanotheranostic Action

4.2. Cellular Uptake and Payload Release

Upon reaching the target site, nanoparticles are internalized primarily via receptor-mediated endocytosis, pinocytosis, or phagocytosis. Once inside the cell, the particles are typically trapped in endosomes. To deliver their payload effectively, they must escape the endosome, often exploiting the "proton sponge" effect or membrane fusion. Stimuli-responsive mechanisms are critical at this stage; carriers may be designed to degrade or undergo conformational changes in response to the acidic endosomal pH (pH 5.0-6.0), high intracellular glutathione levels, or external stimuli like light or magnetic fields [19]. This ensures that the cytotoxic drug is released specifically within the diseased cell, sparing healthy tissue.

Table 2. Stimuli-Responsive Mechanisms for Controlled Drug Release

Type of Stimulus	Trigger	Mechanism of Action	Target Microenvironment
pH (Endogenous)	Acidic pH (5.0–6.5)	Protonation of polymer groups causing swelling or cleavage of acid-labile linkers.	Tumor microenvironment, Endosomes/Lysosomes.
Redox (Endogenous)	High Glutathione (GSH)	Cleavage of disulfide bonds (-S-S-) within the carrier matrix.	Intracellular cytosol of cancer cells (GSH levels are ~100x higher than extracellular).
Enzymatic (Endogenous)	Overexpression of Enzymes (e.g., Cathepsin B, MMPs)	Enzymatic degradation of peptide linkers or polymer backbone.	Tumor stroma, metastatic sites.
Magnetic (Exogenous)	Alternating Magnetic Field (AMF)	Generation of localized heat increases membrane permeability or melts lipid matrix.	Deep-tissue tumors accessible by MRI/Hyperthermia systems.
Light (Exogenous)	Near-Infrared (NIR) Laser	Photothermal conversion causes carrier disruption or phase transition.	Superficial tumors or sites accessible via fiber optics.

4.3. Integrated Imaging and Clearance

Simultaneously, the diagnostic component whether a quantum dot, gold shell, or magnetic core provides real-time imaging data. This allows clinicians to verify the biodistribution of the carrier and the kinetics of drug release. Following therapy, the biodegradation and clearance of the nanocarrier are vital to prevent chronic toxicity. Small particles (typically <5-8 nm) undergo

renal clearance and are excreted via urine, while larger biodegradable polymers are metabolized into non-toxic byproducts or cleared by the hepatobiliary system [20].

5. Synthetic Methodologies

5.1. Bio-Inspired and Green Synthesis

Biomineralization and green synthesis utilize biological templates (proteins, peptides) or natural extracts (plant leaves, fungi) to reduce metal ions into nanoparticles. These bottom-up approaches are eco-friendly, avoiding the use of toxic reducing agents and solvents. They often result in particles with enhanced biocompatibility due to the natural capping agents present in the extracts, which stabilize the nanoparticles and prevent aggregation [21].

Table 3. Comparison of Synthesis Methods

Synthesis Method	Type	Process Description	Advantages	Limitations
Green Synthesis	Biological (Bottom-up)	Reduction of metal ions using plant extracts or microorganisms.	Eco-friendly, non-toxic, natural capping agents improve stability.	Slower reaction rates, difficulty in controlling precise size/shape.
Laser Ablation (LASiS)	Physical (Top-down)	Irradiation of solid targets in liquid solvents with pulsed lasers.	High purity (surfactant-free), suitable for sensitive biological use.	High energy consumption, lower yield compared to chemical methods.
Microwave-Assisted	Chemical/Physical	Use of microwave irradiation for rapid volumetric heating.	Rapid reaction, uniform heating, narrow size distribution.	Requires specialized equipment, potential for "hot spots."
Solution Combustion	Chemical (Exothermic)	Self-sustaining redox reaction between oxidants and fuels.	High energy efficiency, produces highly crystalline/porous materials.	Difficult to control reaction kinetics, often requires high temp.
Polyol Process	Chemical (Reduction)	High-boiling polyalcohol acts as solvent and reducing agent.	Precise control over nucleation/growth, high yield.	Requires organic solvents, post-synthesis purification needed.

5.2. Physical and Chemical Fabrication

5.2.1. Laser Ablation in Solution (LASiS)

Laser ablation is a top-down physical method where a solid target material immersed in a liquid solvent is bombarded with high-intensity pulsed laser beams. This technique causes the ejection of material from the target, which condenses to form nanoparticles. A major advantage of LASiS is the production of high-purity nanoparticles free from chemical surfactants or contaminants, making them ideal for sensitive biomedical applications [22].

5.2.2. Microwave-Assisted Synthesis

Utilizing microwave irradiation provides rapid, uniform volumetric heating of the reaction mixture. This method significantly accelerates reaction rates compared to conventional heating and results in nanoparticles with narrow size distributions and high crystallinity. It is energy-efficient and scalable, suitable for producing complex composite nanomaterials [23].

5.2.3. Solution Combustion Synthesis

Solution combustion is an exothermic redox reaction used primarily for synthesizing metal oxide nanoparticles. It involves a self-sustaining reaction between an oxidant (e.g., metal nitrates) and a fuel (e.g., urea, glycine). The rapid release of gas during the reaction yields porous, crystalline materials with high surface areas, which are suitable for catalytic and imaging applications [24].

5.2.4. Polyol Process

The polyol process is a versatile chemical reduction method where a high-boiling-point polyalcohol (like ethylene glycol) serves as both the solvent and the reducing agent. This method allows for high-temperature hydrolysis and precise control over the nucleation and growth phases, resulting in metal and metal oxide nanoparticles with well-defined shapes and sizes [25].

6. Clinical Applications

6.1. Oncology

In cancer management, nanotheranostics facilitates the early detection of micro-metastases and the precise delivery of chemotherapeutics. Systems like SPIONs allow for pre-operative MRI scanning to delineate tumor boundaries and intra-operative magnetic hyperthermia to kill residual cancer cells. Furthermore, photoacoustic imaging combined with photothermal therapy using gold nanostars has shown promise in eradicating tumors with sub-millimeter precision, allowing for the preservation of healthy margins [26].

6.2. Neurology

Crossing the blood-brain barrier (BBB) is a significant challenge in treating neurodegenerative disorders. Theranostic nanoparticles functionalized with ligands like transferrin or lactoferrin can traverse the BBB via receptor-mediated transcytosis. In Alzheimer's disease, these particles can be designed to bind to amyloid-beta plaques, acting as contrast agents for early diagnosis via PET or MRI while simultaneously delivering siRNA or neuroprotective agents to arrest disease progression [27].

6.3. Infectious Diseases

Nanotheranostics offers rapid pathogen detection via nanosensors and targeted antimicrobial therapy, which is crucial in the era of antibiotic resistance. Functionalized nanoparticles can identify specific bacterial strains or viral antigens. Silver and gold nanoparticles, when conjugated with antibodies, allow for point-of-care diagnosis and can simultaneously deliver antimicrobial peptides directly to the infection site, reducing the systemic side effects of potent antibiotics.

6.4. Cardiovascular Health

In cardiovascular medicine, nanoparticles are engineered to target atherosclerotic plaques. By delivering anti-inflammatory agents directly to the plaque and utilizing MRI to visualize the extent of inflammation, these systems help prevent plaque rupture and subsequent myocardial infarction. Additionally, stem cell-loaded nanocarriers are being explored for regenerative therapy in damaged heart tissue [28].

Table 4. Clinical Applications of Nanotheranostics by Disease State

Disease Category	Target Biomarker/Mechanism	Nanoparticle System	Diagnostic Function	Therapeutic Function
Oncology	Folate Receptors, EGFR, HER2	Gold Nanostars / SPIONs	Photoacoustic Imaging / Pre-operative MRI	Photothermal Ablation / Magnetic Hyperthermia.
Neurology	Amyloid-beta plaques, Transferrin Receptors	Functionalized Liposomes / Quantum Dots	PET/MRI tracking of plaque burden	Delivery of siRNA, neuroprotective agents, or cholinesterase inhibitors.
Infectious Disease	Bacterial surface proteins (e.g., S. aureus)	Silver Nanoparticles (AgNPs) / Silica	SERS-based pathogen detection	Disruption of bacterial cell walls, ROS generation.
Cardiovascular	VCAM-1, Fibrin, Macrophages	Polymer-coated Iron Oxide	MRI visualization of plaque inflammation	Delivery of anti-inflammatory drugs (e.g., statins, steroids).

7. Challenges and Future Perspectives

Despite the transformative potential of nanotheranostics, the transition from laboratory prototypes to clinically approved products is impeded by a multifaceted set of challenges. These hurdles encompass biological safety, manufacturing scalability, regulatory approval pathways, and economic viability.

7.1. Biocompatibility and Toxicity Profiles

The most critical challenge facing nanotheranostics is the comprehensive assessment of long-term biocompatibility. While many materials appear safe in short-term in vitro studies, their in vivo behavior can be unpredictable. Non-biodegradable nanoparticles, such as those based on noble metals or carbon nanotubes, may accumulate in the reticuloendothelial system (liver, spleen) and kidneys, potentially leading to chronic inflammation, oxidative stress, or organ failure over time. The "protein corona" effect, where serum proteins adsorb onto the nanoparticle surface upon entering the bloodstream, can significantly alter the particle's biological identity, affecting targeting efficiency and immune recognition. Future research must focus on developing biodegradable materials and standardizing nanotoxicology protocols to ensure safety profiles are well-understood prior to clinical trials [29].

7.2. Manufacturing and Scalability

Translating nanotheranostic agents from bench to bedside requires robust manufacturing processes that adhere to Good Manufacturing Practice (GMP) standards. Synthesizing complex, multicomponent nanostructures with high batch-to-batch consistency is technically demanding. Slight variations in synthesis conditions can lead to polydispersity in particle size, surface charge, or drug loading efficiency, which can drastically alter therapeutic efficacy. There is a pressing need for the development of scalable, continuous manufacturing technologies, such as microfluidic synthesis, which offers superior control over particle characteristics compared to traditional batch methods.



Figure 3. Development of Nanotheranostics

7.3. Regulatory Guidelines and Economic Factors

The regulatory guidelines for nanotheranostics are inherently complicated because these agents are often classified as "combination products" comprising a drug, a device, and sometimes a biological component. This classification requires rigorous evaluation of each component individually as well as the integrated system, leading to prolonged and costly approval pathways. Regulatory agencies like the FDA and EMA are still evolving their guidelines to address the unique properties of nanomaterials. Furthermore, the high cost of development and manufacturing raises questions about the cost-effectiveness and accessibility of these advanced therapies, particularly for healthcare systems in developing nations.

Table 5. Barriers to Clinical Translation and Strategic Solutions

Challenge	Obstacles	Solutions
Biocompatibility	Accumulation in liver/spleen (RES), oxidative stress, protein corona formation.	Development of biodegradable inorganic hybrids; Surface PEGylation to reduce opsonization.
Manufacturing	Batch-to-batch variability, scaling up complex multistep synthesis, cost.	Microfluidic synthesis for continuous production; Implementation of Quality by Design (QbD) principles.
Regulatory	Classification complexity (Drug vs. Device), lack of standardized testing protocols.	Establishment of specific "nanomedicine" regulatory pathways; Harmonization of international safety standards.
Clinical Efficacy	Poor tumor penetration in fibrotic tumors, heterogeneity of patient response.	Patient stratification using pre-treatment imaging (Personalized Medicine); Use of multistage delivery systems.

7.4. AI and Personalized Profiles

The integration of artificial intelligence (AI) and machine learning with nanotheranostics holds immense promise for the coming years. AI algorithms can predict nanoparticle interactions with biological systems, optimizing design parameters for maximum targeting efficiency and minimal toxicity. Furthermore, the combination of nanotheranostics with patient-specific genomic and proteomic profiles will enable truly personalized medicine, where the theranostic agent is tailored to the unique molecular signature of the patient's disease

8. Conclusion

Nanotheranostics stands at the forefront of the medical revolution, bridging the gap between molecular diagnostics and targeted therapy. These systems offer a level of precision previously unattainable by creating a unified platform for "seeing and treating" disease. The ability to visualize drug delivery in real-time and adapt therapy based on immediate feedback represents a paradigm shift in how we approach complex diseases like cancer and neurodegeneration. While significant engineering, safety, and regulatory challenges persist, the continued interdisciplinary collaboration between materials science, pharmacology, and clinical medicine will likely propel these advanced systems into routine clinical practice, ultimately realizing the goal of fully personalized, accessible, and effective healthcare

References

[1] Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov. 2002;2(2):17-9.

[2] Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2004.

[3] Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics—application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4(6):660-77.

[4] Sharmiladevi P, Girigoswami K, Haribabu V, Girigoswami A. Nano-enabled theranostics for cancer. Mater Adv. 2021;2(9):2876-91.

[5] Zhou J, Rao L, Yu G, Cook TR, Chen X, Huang F. Supramolecular cancer nanotheranostics. Chem Soc Rev. 2021;50(4):2839-91.

[6] Wang LS, Chuang MC, Ho JA. Nanotheranostics—a review of recent publications. Int J Nanomedicine. 2012;7:4679-95.

[7] Wei H, Wang E. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes. Chem Soc Rev. 2013;42(14):6060-93.

[8] Zhang D, Chen Q, Ren Q, Zhong W, Zhang H, Wang G, et al. Transition metal-based nanozymes: Classification, catalytic mechanisms and emerging biomedical applications. Coord Chem Rev. 2024;508:215771.

[9] Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021;9:580118.

[10] Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11):16982-17015.

[11] Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731.

[12] Vines JB, Yoon JH, Ryu NE, Lim DJ, Park H. Gold nanoparticles for photothermal cancer therapy. Front Chem. 2019;7:167.

[13] Argyo C, Weiss V, Bräuchle C, Bein T. Multifunctional mesoporous silica nanoparticles as a universal platform for theranostics. Chem Mater. 2014;26(1):435-51.

[14] Zhang J, Gao M, Gao W, Yang P, Meng F, Liu Q, et al. Functional silver nanoparticles as broad-spectrum antimicrobial agents. New J Chem. 2022;46(34):16387-93.

[15] Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Knüchel R, Kiessling F, et al. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302-25.

[16] Dasari Shareena TP, McShan D, Dasmahapatra AK, Tchounwou PB. A review on graphene-based nanomaterials in biomedical applications and risks in environment and health. Nano-Micro Lett. 2018;10(3):53.

[17] Kumar R, Mondal K, Panda PK, Kaushik A, Abolhassani R, Ahuja R, et al. Core–shell nanostructures: perspectives towards drug delivery applications. J Mater Chem B. 2020;8(39):8992-9027.

[18] Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2(1):3-44.

[19] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.

[20] Li X, Wang B, Zhou S, Chen W, Chen H, Liang S, et al. Surface chemistry governs the sub-organ transfer, clearance and toxicity of functional gold nanoparticles in the liver and kidney. J Nanobiotechnology. 2020;18(1):45.

[21] Singh J, Dutta T, Kim KH, Rawat M, Samddar P, Kumar P. 'Green' synthesis of metals and their oxide nanoparticles: applications for environmental remediation. J Nanobiotechnology. 2018;16(1):84.

[22] Kim M, Osone S, Kim T, Higashi H, Seto T. Synthesis of nanoparticles by laser ablation: A review. KONA Powder Part J. 2017;34:80-90.

[23] Kustov L, Vikanova K. Synthesis of metal nanoparticles under microwave irradiation: Get much with less energy. Metals. 2023;13(10):1714.

[24] Varma A, Mukasyan AS, Rogachev AS, Manukyan KV. Solution combustion synthesis of nanoscale materials. Chem Rev. 2016;116(23):14493-586.

[25] Fiévet F, Ammar-Merah S, Brayner R, Chau F, Giraud M, Mammeri F, et al. The polyol process: a unique method for easy access to metal nanoparticles with tailored sizes, shapes and compositions. Chem Soc Rev. 2018;47(14):5187-233.

[26] Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48(7):2053-108.

[27] Kumar A, Chaudhary RK, Singh R, Singh SP, Wang SY, Hoe ZY, et al. Nanotheranostic applications for detection and targeting neurodegenerative diseases. Front Neurosci. 2020;14:305.

[28] Wu Y, Vazquez-Prada KX, Liu Y, Whittaker AK, Zhang R, Ta HT. Recent advances in the development of theranostic nanoparticles for cardiovascular diseases. Nanotheranostics. 2021;5(4):499-514.

[29] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-51.